| SEC Form 4 |   |
|------------|---|
| FORM       | 4 |

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|  | Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b). |
|--|--|
|--|--|

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL         |           |  |  |  |  |  |  |  |  |
|----------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:          | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average bu | urden     |  |  |  |  |  |  |  |  |

 $|\Gamma|$ 

| Estimated average burden                     |     |
|--|-----|
| Estimated average burden hours per response: | 0.5 |

|   | tisfy the affirmative<br>tions of Rule 10b5-<br>uction 10. |                |  |                   |  |                                       |
|---|--|----------------|--|-------------------|--|---------------------------------------|
| 1. Name and Add<br><u>Ticho Barry</u><br>(Last) | (First)  | (Middle)       | 2. Issuer Name and Ticker or Trading Symbol <u>Stoke Therapeutics, Inc.</u> [STOK] 3. Date of Earliest Transaction (Month/Day/Year) 12/09/2024 |                   | ationship of Reporting P<br>( all applicable)<br>Director<br>Officer (give title<br>below)<br>CHIEF MEDICA | 10% Owner<br>Other (specify<br>below) |
| C/O STOKE T<br>45 WIGGINS                       |  | CS, INC.       |  |                   |  |                                       |
| (Street)<br>BEDFORD<br>(City)                   | MA<br>(State)  | 01730<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Indiv<br>Line) | vidual or Joint/Group Fil<br>Form filed by One Re<br>Form filed by More th<br>Person                       | eporting Person                       |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |                          | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|------------------------------|---|--|---------------|--------------------------|---|--|--|
|                                 |  |   |                              | v | Amount   | (A) or<br>(D) | Price                    | Transaction(s)<br>(Instr. 3 and 4)  | (  | (Instr. 4)                             |
| Common Stock                    | 12/09/2024                                 |   | <b>S</b> <sup>(1)</sup>      |   | 2,586  | D             | \$12.9913 <sup>(2)</sup> | 44,746  | D  |  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| l |   |   |  | uno, 1  | vante                        |   | options, c  |     | 10 30  | cuntics            | ,   |  |   |  |  |
|---|---|---|--|---|------------------------------|---|---|-----|--|--------------------|---|--|---|--|--|
|   | 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | d 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |   |  |   | Code                         | v | (A)   | (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |

### Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.99 to \$13.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

<u>/s/ Jonathan Allan, Attorney-</u> <u>12/11/2024</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.